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Abstract Since the implementation of the mass vaccination campaign against hepatitis B in France, the appearance of
multiple sclerosis, sometimes occurring in the aftermath of vaccinations, led to the publication of epidemiological inter-
national studies. This was also justified by the sharp increase in the annual incidence of multiple sclerosis reported to the
French health insurance in the mid-1990s. Almost 20 years later, a retrospective reflection can be sketched from these
official data and also from the national pharmacovigilance agency. Statistical data from these latter sources seem to show a
significant correlation between the number of hepatitis B vaccinations performed and the declaration to the pharmaco-
vigilance of multiple sclerosis occurring between 1 and 2 years later. The application of the Hill’s criteria to these data
indicates that the correlation between hepatitis B vaccine and multiple sclerosis may be causal.
Keywords Hepatitis B vaccine  Multiple sclerosis  Demyelinating disease  Pharmacovigilance  Vaccine adverse
events
Abbreviations
ANSM Agence nationale de se´curite´ du me´dicament
et des produits de sante´ in French
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CNAM Caisse nationale d’assurance maladie in
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GPRD General Practice Research Database
HB Hepatitis B
MBP Myelin basic protein





R2 Coefficient of determination R-squared
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REVAHB Re´seau vaccin he´patite B in French
VAERS Vaccine Adverse Events Reporting System
WHO World Health Organization
Introduction
The first doubts regarding vaccines as a possible cause or
exacerbation of multiple sclerosis (MS) were formulated
by Miller more than half century ago [1]. Hepatitis B (HB)
vaccine has been the subject of greatest concern, especially
in France where mass HB vaccine administration was
performed in a short time. In 1992, the World Health
Organization (WHO) recommended undertaking a uni-
versal HB vaccination of all young infants in order to
eradicate the HB virus. WHO explained that the teenagers’
vaccination could also be used in addition to or instead of
the vaccination of young children in low-endemic coun-
tries. In 1994, the French health authorities launched a
national vaccination campaign of all pupils in the first year
of secondary school. The following year, HB vaccine was
added to the national immunization program for all young
babies and preteenagers. This intensive campaign had
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quickly exceeded its expected targets by also encouraging
the adult population to be mass-vaccinated, whereas the
vaccination of the infants remained less significant. This
resulted in an unprecedented ‘‘wave’’ of immunization in
adults, with 20 million French individuals vaccinated
against HB, concentrated in 4 years, from 1994 to 1997.
MS cases in some vaccinated adults were rapidly noti-
fied to the French national pharmacovigilance system
(ANSM), triggering investigation by this agency. This
inquiry, started in 1994, was therefore already underway
when French media revealed possible occurrence of post-
immunization MS in 1998. This year, French health
authorities abruptly terminated routine school-based vac-
cination of preteens, and adult HB vaccination began to be
less widespread.
Several epidemiological studies have been evaluating the
correlation between HB vaccination and MS in adults for a
decade. Most of these publications found the absence of a
link [2–6] or a slightly increased risk, but not sufficiently
significant on the statistical level [7–9]. However, different
opinions have also been formulated. A study aiming at
quantifying underreporting in Fourrier’s article [8] was
conducted by D. Costagliola on request of the French phar-
macovigilance. This unpublished study showed by the
‘‘capture–recapture’’ method that the real number of MS
cases linked to HB vaccine was 2–2.5 higher than the offi-
cially registered number [10]. This additional calculation
makes Fourrier’s publication [8] clearly significant. Another
case–control epidemiological study was conducted to eval-
uate serious post-vaccination adverse events registered in the
United States through a spontaneous reporting system in the
VAERS database. Adults receiving HB immunization had
significantly increased odds ratios (OR) for MS (OR 5.2; CI
1.9–20) in comparison with an age-, sex-, and vaccine year-
matched unexposed tetanus-containing vaccine group [11].
A Hernan’s paper, based on a case–control study in the
United Kingdom within the General Practice Research
Database (GPRD), found an increased risk (OR 3.1; CI
1.5–6.3) of MS within the 3 years following HB immuni-
zation [12]. In the same way, a French study on demyelina-
tion in childhood [13] showed that Enge´rix B vaccine
administration was associated with an increased trend of
confirmed MS after 3 years (OR 2.77; CI 1.23–6.24).
On these grounds, we compared temporal HB vaccine
dose distribution and MS occurrence in the French popu-
lation, using the official data collected by the French
pharmacovigilance system (ANSM) and the national health
insurance (CNAM). The results confirmed, at the global
population level, a significant correlation between the
number of immunizations and both the number of MS
cases declared to the pharmacovigilance system 1–2 years




We compared data from two independent national dat-
abases: the National Health Service database (CNAM) [14]
and the French pharmacovigilance system (ANSM) [15].
CNAM
The French general insurance provides each year the
number of new cases of MS in which care is fully sup-
ported. These data are available online on the Web site of
the CNAM [14]. The concerned population represents a
very large majority of people covered by the healthcare
system (83 % of the French population in 1996).
ANSM
This organization identifies spontaneous adverse event
reports emerged in the aftermath of vaccinations since the
beginning of the establishment of HB immunization
(1981). The most common diseases reported were neuro-
logical damages of myelin, known under the generic term
of demyelinating diseases. This condition is clinically
called MS when at least two attacks of demyelination
repeat themselves. When the neurological disorder remains
single, without temporal or spatial diffusion, we speak of
central nervous system demyelination.
The French pharmacovigilance is based on ‘‘spontane-
ous reporting’’ of adverse drug reactions. This allows the
establishment of a possible relationship as well as the
imputability to generate alerts. However, this system
underestimates the real frequency of adverse reactions
(1–10 % of severe side effects are reported) [16].
On the other hand, from 1997, the notification by
REVAHB, the association of victims of HB vaccine,
allowed the completion of these spontaneous reports of
potential side effects. Since its inception, this association
has been able to transmit more than 2,000 files of
individuals who have experienced a neurological problem
of post-vaccine demyelination. However, about a third of
these files are not used by the French pharmacovigilance
(classified as ‘‘not documented’’) when the physician
does not answer to the questionnaire which ANSM sends
him for confirming the diagnosis. Of course, this rate of
not documented files is an obvious factor of
underreporting.
Statistical analyses
We used the R statistical software to compute correlations
and perform linear regressions.




The number of MS was very stable, about 2,500 new cases
each year until 1993. The following years, and especially
since 1996, a progressive increase in the number of new
MS reported to the Health Insurance occurred. This figure
increased to about 4,500 cases in 2003 and remains steady
since.
The annual incidence was 5.3/105 in 1993 and increased
to 8.7/105 insured people a decade later (Fig. 1), which
translates into a 65 % increase in incidence over the
10-year period. These figures are consistent with epide-
miological data published in this country. Indeed, the
incidence of MS in France was estimated at around 4.3/105
inhabitants in the years 1993–1997 from a representative
sample of the Burgundy region [17]. It was reassessed by
the same team at a rate between 7.6 and 8.8/105 inhabitants
for the period 2001–2007, from French CNAM data [18].
Epidemiological studies measuring prevalence of this
disease provide an increase in the same magnitude. This
figure was 40/105 insured people in 1994, at the beginning
of the mass vaccination campaign [19]. It increases rapidly
until 95/105 12 years later [20].
ANSM data analysis
Since the beginning of practicing HB vaccination in France
until December 31, 2010, ANSM has registered 1,650
demyelinating diseases including 1,418 MS. These data are
available online on the Web site of ANSM in the French
national commission for pharmacovigilance of September
27, 2011 [15]. When you draw a distribution curve of MS
reported each year to ANSM in the aftermath of a vaccine
injection, we see that this distribution is neither linear nor
regular, far from it (Fig. 2). There is a huge peak of
reported MS culminating in the years 1995 (229 reports)
and 1996 (246 reports). This peak of post-vaccine neuro-
logical disorders during the period 1994–1998 corresponds,
with an interval of one year, to the beginning of the cam-
paign and intense promotion of the HB vaccination in
France (culminating in the year 1995 with about 23 million
vaccine doses sold).
We studied the correlation between MS data (Y) and
vaccinations data (X). This correlation is high and maxi-
mum (0.9365863) between the number of vaccines sold at
t time (called Xt) and the number of MS occurring the
following year, t ? 1 (called Yt ? 1). There is also a high
correlation (0.7350417) between vaccines sold at t time
(Xt) and the number of reported MS 2 years later (called
Yt ? 2).
If we model this relationship in a linear fashion without
constant (since in the absence of vaccination there are no
MS cases registered by pharmacovigilance), the best model
is one where the coefficient of determination adjusted R2 is
the highest (i.e., = 0.9497).
This model is defined by the relation: Yt ? 2 = ß1Xt ?
ß2Xt ? 1 ? ß3Xt ? 2
The series of sold vaccines at t time (Xt) and 1 year later
(Xt ? 1) have a significant influence (p = 0.00106 for Xt
and 0.02491 for Xt ? 1) on the number of reported MS at
t ? 2 years (Yt ? 2), i.e., 2 years later. But we cannot say
whether the number of vaccines sold in year t ? 2 (Xt ? 2)
has a significant influence (p = 0.07014). Graphically, this
relation is also the model that best fits the peak of reported
MS to ANSM.
It is difficult to adjust the MS data after year 2002. There
is then a notable difference between the theoretical series
(models) and the actual series. This can be explained by the
fact that the number of vaccinations mentioned by ANSM
became less precise figures, rounded and approximate. In
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Fig. 1 Evolution of annual incidence rate of MS supported by the
French health insurance system (CNAM), comparison with annual
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Fig. 2 Sales of Hepatitis B (HB) vaccine every year in France,
comparison with report of post-vaccine MS to the national pharma-
covigilance agency (ANSM) (1984–2010)
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focused on young children. Adult vaccination has become
uncommon, reserved only for high-risk groups. Finally, the
number of MS reported to pharmacovigilance has arguably
become more and more underestimated over the years. The
problem of the emergence of post-vaccine MS had been
widely publicized in the years 1996–1999. Thereafter, over
the years, this problem has been trivialized or forgotten.
Since this period, underreporting became more important.
People who have been victims of adverse events have not
necessarily reminded the physician of the injection of a HB
vaccine some weeks or months before.
Discussion
Are we able to establish a relation between these results
and the Hill’s criteria [21]? Is there a causal relationship
between the HB vaccination and the incidence of MS in
France? The Hill’s criteria for causation include nine items
detailed in Table 1. We will detail now the most important
criteria in the text, the other being a simple bibliographic
reference mentioned in this table.
The current study satisfies the first criterion. The asso-
ciation is highly statistically significant between reported
MS (Yt ? 2) to pharmacovigilance and the series of HB
vaccines that were sold 1 and 2 years before (p \ 0.01 for
sold vaccines 2 years before (Xt) and p \ 0.05 for sold
vaccines 1 year before (Xt ? 1); adjusted R2 = 0.9497).
Although it is possible to demonstrate here a statistical
relationship between the number of sold vaccines and MS
reported to the pharmacovigilance, it is not enough to
affirm an absolute causality. This is a strong signal that
requires further epidemiological studies.
The positive and statistically significant correlation
between HB vaccine exposure and reported MS incidence
is consistently observed in different places, circumstances,
and times (criterion 2).
First, this result is consistent with the Hernan’s case–
control study [12] that found in the British population an
increased risk of MS (OR 3.1; CI 1.5–6.3) in the 3 years
following HB vaccination. Moreover, in this same study,
the risk was greater when the last immunization took place
within the second or third years before first symptoms of
MS (OR 4.1; CI 1.3–13.6).
The results of the case–control study by Geier [11] in
USA are also consistent with the French pharmacovigi-
lance data. There is a very significant change in the risk of
developing MS after HB vaccine in adults in the VAERS
database (OR 5.2, p \ 0.0003; CI 1.9–20).
The Costagiola’s study [10] found underreporting of
post-vaccine reported MS during the observation period
(1994–1996) of an epidemiological study requested by
French pharmacovigilance [9]. The combination of these
two studies suggests a real number of cases significantly
higher (RR = 1.66) than the expected number of MS
during the 3 years of the collection.
Most publications where there is no link between HB
vaccination and the onset of MS [2–5] received grants from
pharmaceutical industry. Other criticism that can be raised
for some of these negative case–control studies is the
limited period (2–24 months) of their survey [4, 7–9].
Moreover, the Hernan’s publication [12] shows also a
negative result (OR 1.8; CI 0.5–6.3) for a period of 1 year
and becomes significant between 2 and 3 years of follow-
up after HB immunization.
The case–control study nested in the Nurses’ Health by
Asherio [4] presents several biases. The vaccination status
was obtained retrospectively like the date of first symptoms
of the disease assessed by questionnaires. This process may
cause selection bias leading to a downwardly biased OR as
the specific (nurses) selected population [26].
At last, a meta-analysis [27], based on six epidemio-
logical case–control studies [4–7, 11, 12], did not find
significant change in the risk of developing MS after HB
Table 1 Study of Hill’s criteria
Criteria Results Comments
1. Strength of the association (appropriate statistical tests) Yes See text
2. Consistency of the observed association Yes See text
3. Specificity of the association No Not applicable to diseases such as MS
4. Temporal relationship of the association Yes See text
5. Biological gradient or dose–response curve No Acceptable when ‘‘the mere presence of the factor
can trigger the effect’’ [21]
6. Biological plausibility Yes See text
7. Coherence with the current knowledge Yes Possible role of the vaccine aluminum adjuvant [22]
8. Experimental or semi-experimental evidence Yes Inducing experimental allergic encephalomyelitis [23, 24]
9. Analogy with similar evidence Yes Occurrence of Guillain–Barre´ syndrome after HB vaccine [25]
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vaccine in adults (OR 0.92; CI 0.84–1.004). This paper can
also be criticized. Strangely, the statistical computing of
this meta-analysis attributes a non-significant value to the
Hernan’ study [12], with an OR 1 (CI 0.5–2.1) by using the
cases’ date of diagnosis as the index date instead of the date
of first symptoms as the author does. But as Hernan wrote
[12], ‘‘the use of dates that are posterior to the true date of
first symptoms may cause a downward bias of the OR for
acute exposures such as vaccinations’’. In addition, the
most significant study by Geier [11] is removed, being
regarded as a ‘‘source of heterogeneity’’. So, withdrawal of
a positive study and changing the result of another one
more easily allows a negative outcome.
Generally speaking, we know that a low risk of adverse
post-vaccination cannot be demonstrated by studies of low
statistical power with small numbers of exposed people.
Therefore, results in a population of over 20 million vac-
cinated people should attract attention and require further
epidemiologic studies. Moreover, studies with a short
period of post-vaccination monitoring are inadequate
because they do not take into account the long biopersis-
tence of immunostimulatory vaccine compounds (such as
aluminum hydroxide) in the body. In this, vaccines dero-
gate from the rule generally used for side effects of drugs.
The temporal relationship (criterion 4) clearly exists
here. The annual incidence of MS recorded by the French
insurance was stable about 5.5/105 until 1995. It rose
sharply in 1996 to stabilize around 8/105 from 1998. But
this sharp increase (65 %) closely follows a major peak in
the number of vaccines sold between 1995 and 1997 in
France (Fig. 1). The number of MS occurring in the
aftermath of a HB vaccination reported to the French
pharmacovigilance almost draws the same peak with a
delay between 1 and 2 years (Fig. 2). Moreover, some
papers report observations of MS relapses triggered by
repeated injections of HB vaccine [28, 29].
The official explanations of the increase in this inci-
dence are twofold, first a better screening of MS whose
diagnosis has been made easier and faster by using radio-
logical data provided by MRI. This is a dubious explana-
tion. This new radiological technique has begun to develop
gradually in French hospitals in 1990 and thus before the
obvious increase in the recruitment of MS by French
national insurance (1996). Otherwise, if this earlier diag-
nosis was really so important in the increased incidence of
MS, we should have observed in France a decrease in the
average age of newly diagnosed cases. And this rejuvena-
tion was not observed [30].
The second factor involves the change in treatment
protocol of this period with the introduction of treatment
with interferon-beta in 1995, an innovative and very
expensive drug that prompted physicians to quickly seek a
total care by French health insurance. In 2004, the
emergence of a new drug (glatiramer), indicated for the
most common form of MS (relapsing–remitting), has not
been followed by an increase in cases registered by CNAM
that year and the following. The incidence remained the
same. This explanation cannot alone explain a so rapid and
significant increase (65 % over 4 years) in the incidence of
a disease like MS.
A third factor must be considered in such a sudden
increase in MS incidence. So the changing of an environ-
mental etiological factor must be taken into account seri-
ously. This therefore appears to be the case for the question
of the potential role of HB vaccination carried out in
France for a short time and in a massive way, about 20
million people concentrated in 4 years. It is interesting to
compare these figures with those countries where routine
vaccination has not been recommended. In Norway, the
incidence of MS is higher than in France in the early
1990 s (8.7/105 between 1990 and 1995). Then, it decrea-
ses slightly in subsequent years (7.2/105 from 1996 to
2000) [31]. In the county of Va¨rmland (Sweden), the
incidence of MS has remained similar (6.4/105) during the
periods 1991–1995 and 1996–2000 [32].
Specificity (criterion 3) is likely for a very specific
population at a specific site and disease. This is not
applicable to diseases such as MS. Genetic risk (HLA-
DR2) and environmental factors (vitamin D insufficiency)
or infectious factors (Epstein–Barr virus, endogenous ret-
roviruses) are clearly involved in the occurrence of MS
although its etiology and pathophysiology are not com-
pletely understood. These other environmental and genetic
factors may have contributed to the raise in MS incidence
and should be mentioned.
Biological plausibility (criterion 6): A plausible mech-
anism between cause and effect is helpful. Are there
explanations regarding plausible mechanisms by which
vaccines and particularly this vaccine may induce harm?
This issue has been extensively studied in recent years.
Various aspects of the causal and temporal interactions
between vaccines and autoimmune phenomena are known,
as well as the possible mechanisms by which different
components of vaccines might induce autoimmunity [33].
A first hypothesis could be the similarity between the
protein S (used in the vaccine against HB) and some
myelin proteins such as PLP (proteolipid proteins) [34].
Another interesting track would be contamination by minor
HB virus polymerase proteins. And we know that HB virus
polymerase shares significant amino acid similarities with
the human MBP (myelin basic protein) [35]. This process
is called molecular mimicry: a foreign antigen that shares
sequence or structural similarities with self-antigens.
Another runway about biological plausibility is to take
into account the metabolism of vaccine adjuvants in the
human body. The long-term persistence of aluminum
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adjuvant at the site of vaccine injection is now well
established [36]. Furthermore, transferring of aluminum
particles from muscle to brain is demonstrated in animals
[37]. A new syndrome entitled ASIA, ‘‘Autoimmune
(Auto-inflammatory) Syndrome Induced by Adjuvants’’,
was recently described, grouping four similar illnesses
[38]. These diseases (siliconosis, the Gulf war syndrome,
the macrophagic myofasciitis syndrome and post-vaccina-
tion phenomena) were linked with previous exposure to an
immune adjuvant (silicone, aluminum salts). In another
publication, the same authors found common clinical
characteristics of the ASIA criteria among 93 patients
diagnosed with immune-mediated conditions post-HB
vaccination, suggesting a common denominator in these
diseases [39].
Conclusions
The figures available in France thus show a definite statis-
tical signal in favor of a causal link between the HB vaccine
event and the apparition of MS with a maximum correlation
in the 2 years following immunization. The impact of other
factors (new use of MRI, beginning of interferon-beta) is
probably associated. The weakness of this study is its ret-
rospective nature and therefore subject to bias of notoriety.
Its strength is that it is based on indisputable official data on
large numbers and during about 12 years. The appearance
of a spectacular ‘‘vaccine wave’’ in France has remained the
only one in its kind. The intensive lobbying carried out in
the years 1994–1997 led to concentrate as many vaccinated
people as possible in the shortest period of time. This par-
ticularity is perhaps the explanation of the emergence of the
problem of post-vaccine MS, especially recorded in this
country. The low overall frequency of this adverse effect,
not measurable in most epidemiological studies, here
becomes more obvious because of a kind of involuntary
very large scale experiment carried out on a third of the
French population. All this is expected to require further
epidemiological studies, particularly from the French health
insurance data. Indeed, CNAM has information on millions
of insured persons for many years that would be usable if we
could more easily access it.
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